Heart failure highlights in 2010

European Journal of Heart Failure

Volumn 13, Issue 4, 2011, Pages 358-363

  Damman, Kevin ^a   Maass, Alexander H ^a   Van Der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Clinical trials; Heart failure; Research

Indexed keywords

ALDOSTERONE ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; BRONCHODILATING AGENT; EPLERENONE; INSULIN; IRON; IVABRADINE; OMEGA 3 FATTY ACID; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; RECOMBINANT ERYTHROPOIETIN; SPIRONOLACTONE; TRANSCRIPTION FACTOR GATA 6;

ANEMIA; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOMYOPATHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEFIBRILLATION; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FAMILIAL CARDIOMYOPATHY; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART HYPERTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERITABILITY; HOSPITALIZATION; HUMAN; HYPERKALEMIA; INCIDENCE; INOTROPISM; KIDNEY DYSFUNCTION; KIDNEY FAILURE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC HEART FAILURE; TELEMONITORING; TREATMENT INDICATION; TREATMENT OUTCOME;

HEART FAILURE; HUMANS;

EID: 79953136773     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr025     Document Type: Review

References (75)

1. Van Veldhuisen DJ, Voors AA, van Gilst WH. The European Journal of Heart Failure in 2010: current impact factor, time-to-first decision, and number of submissions. Eur J Heart Fail 2010;12:895-897.
2. Van Berlo JH, Elrod JW, van den Hoogenhof MM, York AJ, Aronow BJ, Duncan SA, Molkentin JD. The transcription factor GATA-6 regulates pathological cardiac hypertrophy. Circ Res 2010;107:1032-1040.
3. Heineke J, uger-Messier M, Correll RN, Xu J, Benard MJ, Yuan W, Drexler H, Parise LV, Molkentin JD. CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med 2010;16:872-879.
4. Da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el AH, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der NR, van KJ, de WR, de BA, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010;12:1220-1227.
5. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest 2010; 120:3443-3454.
6. Kuipers I, Li J, Vreeswijk-Baudoin I, Koster J, van der HP, Sillje HH, Kuipers F, van Veldhuisen DJ, van Gilst WH, De Boer RA. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail 2010;12: 1042-1050.
7. Fliegner D, Schubert C, Penkalla A, Witt H, Kararigas G, Dworatzek E, Staub E, Martus P, Ruiz NP, Kintscher U, Gustafsson JA, Regitz-Zagrosek V. Female sex and estrogen receptor-beta attenuate cardiac remodeling and apoptosis in pressure overload. Am J Physiol Regul Integr Comp Physiol 2010;298:R1597-R1606.
8. Meems LM, van der HP, van Gilst WH, De Boer RA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets 2011;12: 29-41.
9. De Boer RA, Doehner W, van dH I, Anker SD, Babalis D, Roughton M, Coats AJ, Flather MD, van Veldhuisen DJ. Influence of diabetes mellitus and hyperglycemia on prognosis in patients . or /70 years old with heart failure and effects of nebi-volol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). Am J Cardiol 2010;106: 78-86.
10. Shah AM, Uno H, Kober L, Velazquez EJ, Maggioni AP, MacDonald MR, Petrie MC, McMurray JJ, Califf RM, Pfeffer MA, Solomon SD. The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. Eur J Heart Fail 2010;12:1229-1237.
11. Van den Bergh A, Vangheluwe P, Vanderper A, Carmeliet P, Wuytack F, Janssens S, Flameng W, Holvoet P, Herijgers P. Food-restriction in obese dyslipi-daemic diabetic mice partially restores basal contractility but not contractile reserve. Eur J Heart Fail 2009;11:1118-1125.
12. Malfitano C, ba Loureiro TC, Rodrigues B, Sirvente R, Salemi VM, Rabechi NB, Lacchini S, Curi R, Irigoyen MC. Hyperglycaemia protects the heart after myocar-dial infarction: aspects of programmed cell survival and cell death. Eur J Heart Fail 2010;12:659-667.
13. Von Lewinsky D, Gasser R, Rainer PP, Huber MS, Wilhelm B, Roessl U, Haas T, Wasler A, Grimm M, Bisping E, Pieske B. Functional effects of glucose transporters in human ventricular myocardium. Eur J Heart Fail 2010;12:106-113.
14. Sotoodehnia N, Isaacs A, akker de B, Dorr PI, Newton-Cheh M, Nolte C, van der IM, Muller HP, Eijgelsheim M, Alonso M, Hicks A, Padmanabhan AA, Hayward S, Smith C, Polasek AV, Giovannone O, Fu S, Magnani J, Marciante JW, Pfeufer KD, Gharib A, Teumer SA, Li A, Bis M, Rivadeneira JC, Aspelund F, Kottgen T, Johnson A, Rice T, Sie K, Wang MP, Klopp YA, Fuchsberger N, Wild C, Mateo SH, Estrada LI, Volker K, Wright U, Asselbergs AF, Qu FW, Chakravarti J, Sinner A, Kors MF, Petersmann JA, Harris A, Soliman TB, Munroe EZ, Psaty PB, Oostra BM, Cupples BA, Perz LA, De Boer S, Uitterlinden RA, Volzke AG, Spector H, Liu TD, Boerwinkle FY, Dominiczak E, Rotter AF, van JI, Levy HG, Wichmann D, van Gilst HE, Witteman WH, Kroemer JC, Kao HK, Heckbert WH, Meitinger SR, Hofman T, Campbell A, Folsom H, van Veldhuisen AR, Schwienbacher DJ, O'Donnell C, Volpato CJ, Caulfield CB, Connell MJ, Launer JM, Lu L, Franke X, Fehrmann L, te RS, Groen MG, Weersma HJ, van den RK, Berg LH, Wijmenga C, Ophoff RA, Navis G, Rudan I, Snieder H, Wilson JF, Pramstaller PP, Siscovick DS, Wang TJ, Gudnason V, van Duijn CM, Felix SB, Fishman GI, Jamshidi Y, Stricker BH, Samani NJ, Kaab S, Arking DE. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet 2010;42:1068-1076.
15. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, Loehr LR, Cupples LA, Dehghan A, Lumley T, Rosamond WD, Lieb W, Rivadeneira F, Bis JC, Folsom AR, Benjamin E, Aulchenko YS, Haritunians T, Couper D, Murabito J, Wang YA, Stricker BH, Gottdiener JS, Chang PP, Wang TJ, Rice KM, Hofman A, Heckbert SR, Fox ER, O'Donnell CJ, Uitterlinden AG, Rotter JI, Willerson JT, Levy D, van Duijn CM, Psaty BM, Witteman JC, Boerwinkle E, Vasan RS. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010;3:256-266.
16. Morrison AC, Felix JF, Cupples LA, Glazer NL, Loehr LR, Dehghan A, Demissie S, Bis JC, Rosamond WD, Aulchenko YS, Wang YA, Haritunians T, Folsom AR, Rivadeneira F, Benjamin EJ, Lumley T, Couper D, Stricker BH, O'Donnell CJ, Rice KM, Chang PP, Hofman A, Levy D, Rotter JI, Fox ER, Uitterlinden AG, Wang TJ, Psaty BM, Willerson JT, van Duijn CM, Boerwinkle E, Witteman JC, Vasan RS, Smith NL. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet 2010; 3:248-255.
17. Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-1073.
18. Van den Berg MP, van Spaendonck-Zwarts KY, van Veldhuisen DJ, Gietema JA, Postma A, van Tintelen JP. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity? Eur J Heart Fail 2010;12:1297-1299.
19. Van Tintelen JP, van Spaendonck-Zwarts KY, van den Berg MP. Lamin A/C-related cardiac disease and pregnancy. Eur J Heart Fail 2010;12:532-534.
20. Van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, van der WR, Jongbloed JD, Paulus WJ, Dooijes D, van den Berg MP. Peripartum cardiomyopa-thy as a part of familial dilated cardiomyopathy. Circulation 2010;121:2169-2175.
21. Palojoki E, Kaartinen M, Kaaja R, Reissell E, Karkkainen S, Kuusisto J, Helio T. Pregnancy and childbirth in carriers of the lamin A/C-gene mutation. Eur J Heart Fail 2010;12:630-633.
22. Weidemann F, Niemann M. Screening for Fabry disease using genetic testing. Eur J Heart Fail 2010;12:530-531.
23. Havndrup O, Christiansen M, Stoevring B, Jensen M, Hoffman-Bang J, Andersen PS, Hasholt L, Norremolle A, Feldt-Rasmussen U, Kober L, Bundgaard H. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. Eur J Heart Fail 2010; 12:535-540.
24. Machann W, Breunig F, Weidemann F, Sandstede J, Hahn D, Kostler H, Neubauer S, Wanner C, Beer M. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A. Eur J Heart Fail 2011;13:278-283.
25. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259. (Pubitemid 44079340)
26. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, Berl T, Bobek I, Cruz DN, Daliento L, Davenport A, Haapio M, Hillege H, House A, Katz NM, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P. Cardiorenal syndromes: an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2010; 165:54-67.
27. Damman K, van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010;96:1297-1302.
28. Hata N, Yokoyama S, Shinada T, Kobayashi N, Shirakabe A, Tomita K, Kitamura M, Kurihara O, Takahashi Y. Acute kidney injury and outcomes in acute decompen-sated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail 2010;12:32-37.
29. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
30. Ponikowski P, Mitrovic V, O'Connor CM, Dittrich H, Cotter G, Massie BM, Givertz MM, Chen E, Murray M, Weatherley BD, Fujita KP, Metra M. Haemo-dynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. Eur J Heart Fail 2010;12:1238-1246.
31. Wong LS, Huzen J, van der HP, De Boer RA, Codd V, Westenbrink BD, Benus GF, Voors AA, van Gilst WH, Samani NJ, Jaarsma T, van Veldhuisen DJ. Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure. Eur J Heart Fail 2010;12:348-353.
32. Westenbrink BD, Voors AA, De Boer RA, Schuringa JJ, Klinkenberg T, van der HP, Vellenga E, van Veldhuisen DJ, van Gilst WH. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 2010;12:676-684.
33. Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Mori C, von Eisenhart RB, Pocock S, Poole-Wilson PA, Ponikowski P. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084-1091.
34. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361: 2436-2448.
35. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, Vestbo J, Kjoller E. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 2010;12:685-691.
36. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, Maggioni AP, McMurray JJ. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010;12:557-565.
37. Jankowska EA, Drohomirecka A, Ponikowska B, Witkowska A, Lopuszanska M, Szklarska A, Borodulin-Nadzieja L, Banasiak W, Poole-Wilson PA, Ponikowski P. Deficiencies in circulating testosterone and dehydroepiandroster-one sulphate, and depression in men with systolic chronic heart failure. Eur J Heart Fail 2010;12:966-973.
38. Van Deursen V, Damman K, Hillege HL, van Beek AP, van Veldhuisen DJ, Voors AA. Abnormal liver function in relation to hemodynamic profile in heart failure patients. J Card Fail 2010;16:84-90.
39. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
40. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-622.
41. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-1321. (Pubitemid 36384098)
42. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717. (Pubitemid 29407370)
43. Cleland JG, Coletta AP, Torabi A, Ahmed D, Clark AL. Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III. Eur J Heart Fail 2010;12:1261-1264.
44. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
45. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabra-dine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail 2010;12:75-81.
46. Strauer BE, Yousef M, Schannwell CM. The acute and long-term effects of intra-coronary stem cell transplantation in 191 patients with chronic heARt failure: the STAR-heart study. Eur J Heart Fail 2010;12:721-729.
47. Domian IJ, Buikema JW, De Boer RA, van der MP. Stem cells in heart failure. Eur J Heart Fail 2010;12:642-644.
48. Maxeiner H, Krehbiehl N, Muller A, Woitasky N, Akinturk H, Muller M, Weigand MA, Abdallah Y, Kasseckert S, Schreckenberg R, Schluter KD, Wenzel S. New insights into paracrine mechanisms of human cardiac progenitor cells. Eur J Heart Fail 2010;12:730-737.
49. Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, Hahn A, Fichtner S, Schaefer A, Arseniev L, Ganser A, Drexler H. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J 2009;30:2978-2984.
50. Piepoli MF, Vallisa D, Arbasi M, Cavanna L, Cerri L, Mori M, Passerini F, Tommasi L, Rossi A, Capucci A. Bone marrow cell transplantation improves cardiac, autonomic, and functional indexes in acute anterior myocardial infarction patients (Cardiac Study). Eur J Heart Fail 2010;12:172-180.
51. Achilli F, Malafronte C, Lenatti L, Gentile F, Dadone V, Gibelli G, Maggiolini S, Squadroni L, Di LC, Burba I, Pesce M, Mircoli L, Capogrossi MC, Di LA, Camisasca P, Morabito A, Colombo G, Pompilio G. Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multi-centre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 2010;12:1111-1121.
52. Abdel-Latif A, Bolli R, Zuba-Surma EK, Tleyjeh IM, Hornung CA, Dawn B. Gra-nulocyte colony-stimulating factor therapy for cardiac repair after acute myocar-dial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 2008;156:216-226.
53. Chaudhry SI, Mattera JA, Curtis JP, Spertus JA, Herrin J, Lin Z, Phillips CO, Hodshon BV, Cooper LS, Krumholz HM. Telemonitoring in patients with heart failure. N Engl J Med 2010;363:2301-2309.
54. Piotrowicz E, Baranowski R, Bilinska M, Stepnowska M, Piotrowska M, Wojcik A, Korewicki J, Chojnowska L, Malek LA, Klopotowski M, Piotrowski W, Piotrowicz R. A new model of home-based telemonitored cardiac rehabilitation in patients with heart failure: effectiveness, quality of life, and adherence. Eur J Heart Fail 2010;12:164-171.
55. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009;55:53-60.
56. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301: 383-392.
57. Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlstrom U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure- SIGNAL-HF (Swedish Intervention study-Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 2010;12:1300-1308.
58. Desai A, Lewis E, Solomon S, McMurray JJ, Pfeffer M. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail 2010;12:936-942.
59. Van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95: 1309-1314.
60. Jin B, Luo X, Lin H, Li J, Shi H. A meta-analysis of erythropoiesis- stimulating agents in anaemic patients with chronic heart failure. Eur J Heart Fail 2010; 12:249-253.
61. Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, Vriz O, Pasotti M, Gorini M, Marchioli R, Maggioni A, Tavazzi L. Effects of n23 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010;12:1345-1353.
62. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010;12:1143-1153.
63. Lubitz SA, Leong-Sit P, Fine N, Kramer DB, Singh J, Ellinor PT. Effectiveness of cardiac resynchronization therapy in mild congestive heart failure: systematic review and meta-analysis of randomized trials. Eur J Heart Fail 2010;12:360-366.
64. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 2010;363:2385-2395.
65. Chung ES, Katra RP, Ghio S, Bax J, Gerritse B, Hilpisch K, Peterson BJ, Feldman DS, Abraham WT. Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction .35%: a PROSPECT trial substudy. Eur J Heart Fail 2010;12:581-587.
66. Maass AH, van Veldhuisen DJ. Device therapy in patients with heart failure and preserved ejection fraction (HFPEF): a new frontier? Eur J Heart Fail 2010;12: 527-529.
67. Schaer BA, Osswald S, Di VM, Soliman OI, Sticherling C, ten Cate FJ, Jordaens L, Theuns DA. Close connection between improvement in left ventricular function by cardiac resynchronization therapy and the incidence of arrhythmias in cardiac resynchronization therapy-defibrillator patients. Eur J Heart Fail 2010;12: 1325-1332.
68. Ellenbogen KA, Gold MR, Meyer TE, Fernndez LI, Mittal S, Waggoner AD, Lemke B, Singh JP, Spinale FG, Van Eyk JE, Whitehill J, Weiner S, Bedi M, Rapkin J, Stein KM. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchroniza-tion therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography- guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010;122:2660-2668.
69. Foley PW, Chalil S, Khadjooi K, Irwin N, Smith RE, Leyva F. Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy. Eur J Heart Fail 2011;13:43-51.
70. Poole JE, Gleva MJ, Mela T, Chung MK, Uslan DZ, Borge R, Gottipaty V, Shinn T, Dan D, Feldman LA, Seide H, Winston SA, Gallagher JJ, Langberg JJ, Mitchell K, Holcomb R. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010;122:1553-1561.
71. Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2010; 122:1265-1271.
72. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, Theuns D, Park RE, Wright DJ, Connelly DT, Fynn SP, Murgatroyd FD, Sperzel J, Neuzner J, Spitzer SG, Ardashev AV, Oduro A, Boersma L, Maass AH, Van GI, Wilde AA, van Dessel PF, Knops RE, Barr CS, Lupo P, Cappato R, Grace AA. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010;363:36-44.
73. Sagic D, Otasevic P, Sievert H, Elsasser A, Mitrovic V, Gradinac S. Percutaneous implantation of the left ventricular partitioning device for chronic heart failure: a pilot study with 1-year follow-up. Eur J Heart Fail 2010;12:600-606.
74. Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J. Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail 2010;12:181-185.
75. Edelmann F, Schmidt AG, Gelbrich G, Binder L, Herrmann-Lingen C, Halle M, Hasenfuss G, Wachter R, Pieske B. Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolac-tone on exercise capacity and diastolic function in patients with symptomatic dias-tolic heart failure (Aldo-DHF). Eur J Heart Fail 2010;12:874-882.